Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Evaluating the Barrier Function, Regenerative Capacity, and Soft Tissue Outcomes of Acellular Dermal Matrix

21. Mai 2026 aktualisiert von: Maria L. Geisinger, DDS, MS, University of Alabama at Birmingham

A Prospective, Double-Arm, Randomized Controlled Trial Evaluating the Barrier Function, Regenerative Capacity, and Soft Tissue Outcomes of Acellular Dermal Matrix Compared to Resorbable Collagen Membranes in Edentulous Ridge Augmentation

This investigator-initiated study will compare ADM and resorbable cross-linked collagen membrane barriers for guided bone regeneration at atrophic lateral ridge augmentation sites.

Studienübersicht

Detaillierte Beschreibung

This investigator-initiated study will compare ADM and resorbable collagen membrane barrier for guided bone regeneration. Systematic reviews and randomized clinical trials confirm that resorbable collagen membranes combined with particulate graft materials predictably increase horizontal ridge width, typically achieving gains of approximately 3-5 mm at 6 months.3,5 The biologic mechanism involves clot stabilization, space maintenance (often supported with fixation tacks or tenting screws), and exclusion of competing soft tissue cells.3 Despite these predictable outcomes, collagen membranes possess inherent limitations, including limited intrinsic structural rigidity, susceptibility to enzymatic degradation when exposed6 and lack of contribution to gingival phenotype modification.

In contrast, human data evaluating acellular dermal matrix (ADM) as a barrier membrane in horizontal guided bone regeneration is limited. One of the earliest clinical and histologic investigations evaluated ADM in the management of Seibert Class I horizontal ridge defects using particulate grafting and reported both clinical ridge width improvement and histologic evidence of new vital bone formation.12 Notably, the authors also observed increased soft tissue thickness at treated sites, suggesting a potential dual hard- and soft-tissue benefit for its use. However, this study was a single-arm design without a direct comparator group, limiting the ability to determine whether outcomes were equivalent or superior to those achieved with conventional collagen membranes.

The majority of human ADM literature focuses on periodontal plastic surgery applications rather than GBR, including tooth root coverage procedures to treat gingival recession,10 peri-implant soft tissue augmentation,15 and keratinized tissue (KT) augmentation techniques.16 These investigations consistently demonstrate increased mucosal thickness and KT width with ADM use, reinforcing its soft tissue regenerative capacity. Nevertheless, these outcomes cannot be extrapolated directly to horizontal ridge augmentation without controlled comparative data.

Preclinical animal studies provide additional biologic rationale. It has been demonstrated in a canine GBR model that ADM functioned as an effective barrier membrane, with histologic evidence of new bone formation comparable to bioabsorbable membranes.17 Additional animal studies have shown that ADM supports vascular infiltration, integrates into host tissues, and maintains an acceptable inflammatory profile during early healing.18 Histomorphometric analyses in these models report woven bone formation beneath ADM at early intervals, followed by progressive remodeling into lamellar bone. While these findings support the biologic plausibility of ADM as a GBR membrane, animal data cannot substitute for controlled human clinical trials.16-19 Importantly, no adequately powered human randomized controlled trial has directly compared ADM and resorbable cross-linked collagen membranes head-to-head in horizontal ridge augmentation with GBR using standardized volumetric CBCT analysis, histomorphometric evaluation of post-healing bone biopsy, and longitudinal soft tissue assessment. Existing studies either evaluate collagen membranes alone,3,5 assess ADM in non-comparative design,12 or evaluate ADM and other autogenous, xenogeneic, or allogeneic soft tissue grafts for phenotype modification without simultaneous GBR.10,14,15 Consequently, it remains unclear whether ADM provides equivalent bone volume augmentation, histologic bone formation, and if it confers additional soft tissue benefits in the context of ridge augmentation, or whether its clinical performance differs in the setting of membrane exposure.

This absence of direct comparative human data represents a critical gap in the literature and provides the rationale for a randomized controlled trial evaluating ADM versus resorbable collagen membranes in horizontal guided bone regeneration.

Studientyp

Interventionell

Einschreibung (Geschätzt)

70

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

  • Name: Sarah Startley, DMD
  • Telefonnummer: 205-975-8711
  • E-Mail: ss1971@uab.edu

Studieren Sie die Kontaktsicherung

  • Name: Maria Geisinger, DDS, MS
  • Telefonnummer: 205-934-4984
  • E-Mail: miagdds@uab.edu

Studienorte

    • Alabama
      • Birmingham, Alabama, Vereinigte Staaten, 35294
        • University of Alabama at Birmingham
        • Kontakt:
          • Sarah Startley, DMD
          • Telefonnummer: 205-975-8711
          • E-Mail: ss1971@uab.edu
        • Kontakt:
          • Maria Geisinger, DDS, MS
          • Telefonnummer: 205-934-4984
          • E-Mail: miagdds@uab.edu
        • Hauptermittler:
          • Maria Geisinger, DDS, MS

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Ja

Beschreibung

Inclusion Criteria:

  • English speaking
  • At least 18 years old
  • Must be a patient of the UAB Dental School
  • Able to read and understand informed consent document
  • Patients presenting with a diagnosed need horizontal ridge augmentation with GBR without simultaneous implant placement, to allow for future dental implant placement.
  • Presence of periodontally healthy, non-carious neighboring teeth and/or healthy restored dental implants on either side of the edentulous span planned for GBR, or unhealthy adjacent teeth to be extracted during the same visit.
  • ≤4 mm ridge width in a Seibert Class I Edentulous span19
  • No anticipated need for surgical and/or endodontic care at planned teeth adjacent to the proposed surgical site during the study period.

Exclusion Criteria:

  • Non-English speaking
  • Less than 18 years old
  • Smokers/nicotine users (defined as currently reporting use of any form of tobacco/nicotine products)
  • Patients with systemic pathologies or conditions contraindicating oral surgical procedures or adversely affecting wound healing, including:

    • Uncontrolled diabetes (HbA1c > 7%)
    • Untreated periodontal disease
    • History of head/neck radiation
    • IV bisphosphonates
    • Immunocompromised state
    • Pregnancy
    • Acute infection at site
  • Documented or suspected allergy or sensitivity to any study product

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Guided Bone Regeneration with ADM (AlloDerm) as a barrier
GBR will be performed using a composite particulate graft consisting of a combination of freeze-dried bone allograft (FDBA) and xenograft in a 75%/25% mixture. Following decortication and graft placement to reconstruct the horizontal ridge deficiency, acellular dermal matrix (ADM) will be adapted to fully cover the augmented site with appropriate extension beyond the defect margins. The ADM will be stabilized using titanium tacks and/or periosteal sutures as needed to ensure space maintenance and membrane stability.
GBR will be performed using a composite particulate graft consisting of a combination of freeze-dried bone allograft (FDBA) and xenograft in a 75%/25% mixture. Following decortication and graft placement to reconstruct the horizontal ridge deficiency, acellular dermal matrix (ADM) will be adapted to fully cover the augmented site with appropriate extension beyond the defect margins. The ADM will be stabilized using titanium tacks and/or periosteal sutures as needed to ensure space maintenance and membrane stability.
Aktiver Komparator: Guided Bone Regeneration with Resorbable Crosslinked Collagen Matrix (Mem-Lok) as a barrier
GBR will be performed using a composite particulate graft consisting of a combination of freeze-dried bone allograft (FDBA) and xenograft in a 75%/25% mixture. The graft will be contoured to reconstruct the horizontal ridge deficiency following decortication of the recipient site. A resorbable collagen membrane [Mem-Lok® Resorbable Collagen Matrix (RCM) will be trimmed and positioned to fully cover the grafted area with extension beyond the defect margins and stabilized using titanium tacks and/or periosteal sutures as needed.
GBR will be performed using a composite particulate graft consisting of a combination of freeze-dried bone allograft (FDBA) and xenograft in a 75%/25% mixture. The graft will be contoured to reconstruct the horizontal ridge deficiency following decortication of the recipient site. A resorbable collagen membrane [Mem-Lok® Resorbable Collagen Matrix (RCM) will be trimmed and positioned to fully cover the grafted area with extension beyond the defect margins and stabilized using titanium tacks and/or periosteal sutures as needed.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Horizontal ridge width gain
Zeitfenster: baseline to 6 months
Horizontal ridge width gain (mm) at 6 months post-GBR (CBCT-based measurement) at 2mm and 4mm from the alveolar crest
baseline to 6 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Soft tissue thickness change
Zeitfenster: 9 months
Clinical assessment using an endodontic reamer and a calibrated periodontal probe
9 months
Patient centered outcomes using the Visual Analog Scale (VAS)
Zeitfenster: 4 weeks
Patient centered outcomes including pain, bleeding, swelling, change in daily activities at 2 weeks and 4 weeks postoperatively, using the Visual Analog Scale (VAS)
4 weeks

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Maria L Geisinger, DDS, MS, University of Alabama at Birmingham

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Oktober 2026

Primärer Abschluss (Geschätzt)

1. Oktober 2027

Studienabschluss (Geschätzt)

1. Oktober 2028

Studienanmeldedaten

Zuerst eingereicht

21. Mai 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

21. Mai 2026

Zuerst gepostet (Tatsächlich)

29. Mai 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

29. Mai 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

21. Mai 2026

Zuletzt verifiziert

1. Mai 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • IRB-300016808
  • UAB Periodontology (Andere Kennung: University of Alabama at Birmingham)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

Data from this study will not be shared with other researchers outside of our research team.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Azelluläre dermale Matrix

Abonnieren